Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal pharmaceutical products. The company's portfolio spans acute care, emergency medicine, and chronic disease management. Key branded products include BAQSIMI (glucagon nasal spray for severe hypoglycemia), Primatene Mist (over-the-counter epinephrine inhaler for asthma), and Cortrosyn (diagnostic agent). The company also manufactures a broad range of generic injectables including enoxaparin, naloxone, epinephrine, lidocaine formulations, morphine, lorazepam, and vasopressin, along with specialty products such as Amphadase (hyaluronidase injection) and Regadenoson (cardiac stress imaging agent).

The company operates manufacturing and distribution capabilities across the United States, China, and France. Beyond finished pharmaceutical products, Amphastar distributes recombinant human insulin and porcine insulin active pharmaceutical ingredients. The development pipeline includes generic injectable and inhalation products, biosimilar candidates, and intranasal epinephrine formulations for allergic reactions.

Amphastar was founded in 1996 and maintains headquarters in Rancho Cucamonga, California. The company operates as a specialty and generic pharmaceutical manufacturer with a market capitalization of approximately $1.2 billion, competing in the competitive injectable and inhalation drug segments where manufacturing scale, regulatory compliance, and product portfolio breadth are primary competitive factors.